Abstract
Almost 200 million people worldwide are found to be affected by Diabetes mellitus (DM). DM is a metabolic disorder which occurs due to reduced insulin action and/or insulin secretion in the body. Reduced or inactive insulin results in imbalanced food metabolism. With the progression of disease, pathological changes like nephropathy, retinopathy and cardiovascular complications start occurring in the body. DM is mainly categorized into 2 types: type 1 DM and type 2 DM. Type 1 is generally treated through insulin replacement therapy. Type 2 DM is treated with oral hypoglycemics. Oral hypoglycemics are classified into 5 types: sulfonylureas, biguanides, α-glucosidase inhibitors, meglitinide analogues and thiazolidinediones. Conventional dosage forms of most of these drugs bear some drawbacks such as frequent dosing, short half live, and low bioavailability. Therefore, to alleviate the drawbacks associated with conventional dosage forms, efforts have been made in the area of novel and controlled drug delivery system for oral hypoglycemics. Present review highlights various novel and controlled drug delivery systems that have been investigated by different researchers for achieving sustained and controlled drug delivery of oral hypoglycemics and for overcoming the limitations related with the conventional dosage forms of oral hypoglycemics.
Keywords: Diabetics, Oral hypoglycemics, Conventional therapy, Novel Drug Delivery Systems, Sustained release, Marketed formulations.
Current Drug Delivery
Title:Recent Advances in Drug Delivery Systems for Anti-Diabetic Drugs: A Review
Volume: 11 Issue: 4
Author(s): Meenu Grover and Puneet Utreja
Affiliation:
Keywords: Diabetics, Oral hypoglycemics, Conventional therapy, Novel Drug Delivery Systems, Sustained release, Marketed formulations.
Abstract: Almost 200 million people worldwide are found to be affected by Diabetes mellitus (DM). DM is a metabolic disorder which occurs due to reduced insulin action and/or insulin secretion in the body. Reduced or inactive insulin results in imbalanced food metabolism. With the progression of disease, pathological changes like nephropathy, retinopathy and cardiovascular complications start occurring in the body. DM is mainly categorized into 2 types: type 1 DM and type 2 DM. Type 1 is generally treated through insulin replacement therapy. Type 2 DM is treated with oral hypoglycemics. Oral hypoglycemics are classified into 5 types: sulfonylureas, biguanides, α-glucosidase inhibitors, meglitinide analogues and thiazolidinediones. Conventional dosage forms of most of these drugs bear some drawbacks such as frequent dosing, short half live, and low bioavailability. Therefore, to alleviate the drawbacks associated with conventional dosage forms, efforts have been made in the area of novel and controlled drug delivery system for oral hypoglycemics. Present review highlights various novel and controlled drug delivery systems that have been investigated by different researchers for achieving sustained and controlled drug delivery of oral hypoglycemics and for overcoming the limitations related with the conventional dosage forms of oral hypoglycemics.
Export Options
About this article
Cite this article as:
Grover Meenu and Utreja Puneet, Recent Advances in Drug Delivery Systems for Anti-Diabetic Drugs: A Review, Current Drug Delivery 2014; 11 (4) . https://dx.doi.org/10.2174/1567201811666140118225021
DOI https://dx.doi.org/10.2174/1567201811666140118225021 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Radioprotective Effect of Gliclazide as an Anti-Hyperglycemic Agent Against Genotoxicity Induced by Ionizing Radiation on Human Lymphocytes
Cardiovascular & Hematological Agents in Medicinal Chemistry Vaccines For Type 1 Diabetes: Prevention or Reversal?
Current Diabetes Reviews Diabetes-induced Alterations in HDL Subfractions Distribution
Current Pharmaceutical Design Risk Factors for Cardiovascular Events in Japanese Patients Treated with Fluvastatin from the Long-Term Event Monitoring (LEM) Study
Current Vascular Pharmacology Evaluation of the Effects of 1,25 Vitamin D3 on Regulatory T Cells and T Helper 17 Cells in Vitamin D-deficient Women with Unexplained Recurrent Pregnancy Loss
Current Molecular Pharmacology Transient Receptor Potential Vanilloid 1 Channel Modulation: A Novel Approach to Pain Therapy
Current Bioactive Compounds The Effects of Tamoxifen on Immunity
Current Medicinal Chemistry Preparation and Evaluation of Buccal Bioadhesive Tablets Containing Clotrimazole
Current Drug Delivery Rheumatological Diseases in HIV Infection
Current Rheumatology Reviews Shoulder Manifestations of Diabetes Mellitus
Current Diabetes Reviews A Review of Pharmacokinetic Parameters of Metabolites and Prodrugs
Drug Metabolism Letters Nitric Oxide, Peroxynitrite, Peroxynitrous Acid, Nitroxyl, Nitrogen Dioxide, Nitrous Oxide: Biochemical Mechanisms and Bioaction
Current Bioactive Compounds Current Reviews on Renal Vein Thrombosis in Neonates
Current Pediatric Reviews Novel Targets of Metformin in Cardioprotection: Beyond the Effects Mediated by AMPK
Current Pharmaceutical Design Lipid-Lowering Therapy in HIV-Infected Patients: Relationship with Antiretroviral Agents and Impact of Substance-Related Disorders
Current Vascular Pharmacology The Effects of Obesity on the Cerebral Vasculature
Current Vascular Pharmacology Regression of Oxidative Stress by Targeting eNOS and Nrf2/ARE Signaling: A Guided Drug Target for Cardiovascular Diseases
Current Topics in Medicinal Chemistry Antifungal Drugs for Systemic Mycosis: An Overview of Mechanism of Action and Resistance
Anti-Infective Agents in Medicinal Chemistry Nanomedicine against Alzheimer’s and Parkinson’s Disease
Current Pharmaceutical Design Editorial: Modifying Cardiovascular Risk Factors: Acquired Topics and Emerging Concepts
Current Pharmaceutical Design